Trademark/Service Mark Application, Principal Register
PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER
Principal
APPLICANT INFORMATION
*OWNER OF MARK
ModernaTx, Inc.
*MAILING ADDRESS
200 Technology Square, 2nd Floor
*CITY
Cambridge
*STATE
(Required for U.S. applicants)
Massachusetts
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
United States
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
02139
*EMAIL ADDRESS
XXXX
LEGAL ENTITY INFORMATION
TYPE
corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION
Delaware
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS
001
*IDENTIFICATION
Medical, biological, and pharmaceutical preparations for scientific, research, medical laboratory use, or for the manufacture of
pharmaceuticals, namely, preparations containing messenger RNA for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders,
inflammatory disorders, immunoregulatory disorders, and metabolic disorders,; biochemicals for in vivo, ex vivo, or in vitro scientific research and medical research, namely, for use in the
manufacture of pharmaceuticals for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders,
immunoregulatory disorders, metabolic disorders,; lipid nanoparticles for scientific, laboratory or medical research use
FILING BASIS
SECTION 1(b)
INTERNATIONAL CLASS
005
*IDENTIFICATION
Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger
RNA for preventing and treating viruses, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, and
respiratory disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention and treatment of viruses rare diseases, cancers, neurological disorders,
cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, and respiratory disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes;
drug carriers for medical use, namely, lipid nanoparticles for delivering drugs; lipid nanoparticles for drug delivery sold as an integral component of drugs; pharmaceutical preparations, namely,
messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
FILING BASIS
SECTION 1(b)
INTERNATIONAL CLASS
042
*IDENTIFICATION
Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design
and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and
scientific research in the fields of pharmaceuticals and vaccines
FILING BASIS
SECTION 1(b)
ATTORNEY INFORMATION
NAME
Keith Barritt
ATTORNEY DOCKET NUMBER
425470187001
ATTORNEY BAR MEMBERSHIP NUMBER
XXX
YEAR OF ADMISSION
XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY
XX
FIRM NAME
Fish & Richardson P.C.
STREET
P.O. Box 1022
CITY
Minneapolis
STATE
Minnesota
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
United States
ZIP/POSTAL CODE
55440-1022
PHONE
612-335-5070
FAX
877-769-7945
EMAIL ADDRESS
tmdoctc@fr.com
OTHER APPOINTED ATTORNEY
Vivian Cheng, Kristen McCallion, John P. McCormick, P. Weston Musselman, Jr., Debra S. Serota, Catherine H. Stockell, Jerre B. Swann, Jr.,
Lisa Greenwald-Swire, Ryan Thomas, Kerrijane John, Sarah Kelleher, Charles Bahlert, Jenifer deWolf Paine, Ryan Steinman, Amanda Kusnierz, Darra Loganzo, Laya Varanasi, Nathan Ranns, Meredith Bayer
and Cynthia Johnson Walden
CORRESPONDENCE INFORMATION
NAME
Keith Barritt
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE
tmdoctc@fr.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)
barritt@fr.com; webber@fr.com
FEE INFORMATION
APPLICATION FILING OPTION
TEAS Standard
NUMBER OF CLASSES
3
APPLICATION FOR REGISTRATION PER CLASS
350
*TOTAL FEES DUE
1050
*TOTAL FEES PAID
1050
SIGNATURE INFORMATION
SIGNATURE
/John Ward/
SIGNATORY'S NAME
John Ward
SIGNATORY'S POSITION
Vice President, Associate General Counsel, Trademarks
SIGNATORY'S PHONE NUMBER
612 204 4664
DATE SIGNED
07/01/2022
SIGNATURE METHOD
Sent to third party for signature
PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Serial Number:97486095
Filing Date:07/01/2022
To the Commissioner for Trademarks:
MARK: mFUSion (Standard Characters, see mark)
The literal element of the mark consists of mFUSion. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, ModernaTx, Inc., a corporation of Delaware, having an address of
200 Technology Square, 2nd Floor
Cambridge, Massachusetts 02139
United States
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 001: Medical, biological, and pharmaceutical preparations for scientific, research, medical laboratory use, or for the manufacture of pharmaceuticals, namely, preparations
containing messenger RNA for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory
disorders, and metabolic disorders,; biochemicals for in vivo, ex vivo, or in vitro scientific research and medical research, namely, for use in the manufacture of pharmaceuticals for preventing and
treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders,; lipid
nanoparticles for scientific, laboratory or medical research use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
International Class 005: Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and
treating viruses, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, and respiratory disorders;
mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention and treatment of viruses rare diseases, cancers, neurological disorders, cardiovascular disorders,
inflammatory disorders, immunoregulatory disorders, metabolic disorders, and respiratory disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes; drug carriers for medical
use, namely, lipid nanoparticles for delivering drugs; lipid nanoparticles for drug delivery sold as an integral component of drugs; pharmaceutical preparations, namely, messenger RNA and delivery
agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
International Class 042: Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical
technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the
fields of pharmaceuticals and vaccines
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
The owner's/holder's proposed attorney information: Keith Barritt. Other appointed attorneys are Vivian Cheng, Kristen McCallion, John P. McCormick, P. Weston Musselman, Jr., Debra S. Serota,
Catherine H. Stockell, Jerre B. Swann, Jr., Lisa Greenwald-Swire, Ryan Thomas, Kerrijane John, Sarah Kelleher, Charles Bahlert, Jenifer deWolf Paine, Ryan Steinman, Amanda Kusnierz, Darra Loganzo,
Laya Varanasi, Nathan Ranns, Meredith Bayer and Cynthia Johnson Walden. Keith Barritt of Fish & Richardson P.C., is a member of the XX bar, admitted to the bar in XXXX, bar membership no.
XXX, and the attorney(s) is located at
P.O. Box 1022
Minneapolis, Minnesota 55440-1022
United States
612-335-5070(phone)
877-769-7945(fax)
tmdoctc@fr.com
The docket/reference number is 425470187001.
Keith Barritt submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S.
Commonwealth or territory.
The applicant's current Correspondence Information:
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed,
and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $1050 has been submitted with the application, representing payment for 3 class(es).
Declaration
Declaration Signature
Signature: /John Ward/ Date: 07/01/2022
Signatory's Name: John Ward
Signatory's Position: Vice President, Associate General Counsel, Trademarks
Signatory's Phone Number: 612 204 4664
Signature method: Sent to third party for signature
Payment Sale Number: 97486095
Payment Accounting Date: 07/01/2022
Serial Number: 97486095
Internet Transmission Date: Fri Jul 01 16:18:11 ET 2022
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XXX-202207011618119
49781-97486095-820d592aad3de6970a6e9c8cc
dcc78469e4a4acfa50ea1e54cdaf8bd1b875571f
8-DA-18111216-20220701101334829450